News | October 09, 2014

Manchester Researchers Believe Immunotherapy Could Stop Resistance to Radiotherapy

October 9, 2014 — Treating cancers with immunotherapy and radiotherapy at the same time could stop them from becoming resistant to treatment, according to a study published in Cancer Research.

The researchers, based at the University of Manchester in the United Kingdom and funded by MedImmune, the global biologics research and development arm of AstraZeneca, and Cancer Research UK, found that combining the two treatments helped the immune system hunt down and destroy cancer cells that weren't killed by the initial radiotherapy in mice with breast, skin and bowel cancers.

Radiotherapy is a successful treatment for many forms of cancer, but in cancer cells that it doesn't kill it can switch on a 'flag' on their surface, called PD-L1, that tricks the body's defenses into thinking that cancerous cells pose no threat. The immunotherapy works by blocking these 'flags' to reveal the true identity of cancer cells. The approach improved survival and protected the mice against the disease from returning.

Simon Dovedi, Ph.D., the lead researcher based at the University of Manchester and member of the Manchester Cancer Research Center, said: "Using the body's own defenses to treat cancers has huge potential with early phase clinical trials demonstrating exciting patient benefit but we are still at the early stages of understanding how best to use these types of treatments. Combining certain immunotherapies with radiotherapy could make them even more effective and we're now looking to test this in clinical trial to see just how much of a difference it could make."

"Around half of all cancer patients are given radiotherapy, and it has been at the heart of helping improve survival rates so that today one in two cancer patients will survive for at least ten years. Doctors and researchers are constantly looking for ways to improve treatments, and this approach could open the door to a whole new way of giving radiotherapy," said Nic Jones, Cancer Research UK's chief clinician.

Robert Wilkinson, director of oncology research at MedImmune, said, "MedImmune is committed to developing strong science-led collaborations and supporting research that helps further advance our scientific understanding in the important area of immunotherapy. The findings described in the recent study with Cancer Research UK are extremely encouraging."

Cancer Research UK joined forces with the Christie NHS Foundation Trust and the University of Manchester to form the Manchester Cancer Research Center, allowing doctors and scientists to work closely together to turn scientific advances into patient benefits sooner.

For more information: www.cancerresearchuk.org

Related Content

IBA Releases Razor Nano Ionization Chamber
News | Proton Therapy | September 22, 2017
September 22, 2017 — IBA (Ion Beam Applications S.A.) announced the release of the Razor Nano Chamber, the smallest a
Penn Medicine Treats World's First Patient on Varian's Halcyon System
News | Radiation Therapy | September 22, 2017
September 22, 2017 — Varian Medical Systems announced a patient at Penn Medicine, with head & neck cancer, became
BrainLAB Announces FDA Clearance For Two New Indication-Specific Radiosurgery Software Applications
Technology | Treatment Planning | September 21, 2017
Brainlab announced that it has received U.S. Food and Drug Administration (FDA) clearance for Elements Spine SRS and...
Accuray Showcases CyberKnife and Radixact Systems at ASTRO 2017
News | Radiation Therapy | September 21, 2017
Accuray Inc. announced that data and first-hand experience with its advanced CyberKnife and Radixact Systems will be...
RayCare Oncology Information System Being Shown at ASTRO 2017
News | Radiation Therapy | September 20, 2017
RaySearch will be exhibiting its next-generation oncology information system (OIS) RayCare, among other highlights, at...
ProCure Proton Therapy Center New Jersey Celebrates Five-Year Cancer-Free Milestone for Prostate Cancer Patients
News | Proton Therapy | September 20, 2017
ProCure Proton Therapy Center in Somerset, N.J., recently celebrated the five-year cancer-free milestone for the first...
Varian to Showcase Latest Radiation Therapy Technologies and Software at ASTRO 2017
News | Radiation Therapy | September 19, 2017
Varian Medical Systems announced it will be demonstrating its new Halcyon platform and HyperArc high-definition...
Elekta to Highlight MOSAIQ Oncology Analytics at ASTRO Annual Meeting
News | Radiation Therapy | September 19, 2017
September 19, 2017 — Elekta will highlight its Mosaiq Oncology...
Theraclion to Launch Metastatic Breast Cancer Trial Combining Echotherapy and Immunotherapy
News | Focused Ultrasound Therapy | September 18, 2017
September 18, 2017 — Theraclion and co-lead investigator David Brenin, M.D., from the University of Virginia School o
Overlay Init